Epstein-Barr Virus: An Infrequent Pathogen of Acute Undifferentiated Febrile Illness From a Tertiary Care Hospital in Southern India

Review began 09/02/2021

Review ended 09/22/2021

Published 09/23/2021

© Copyright 2021

Dhodapkar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Rahul Dhodapkar¹, Mugunthan M², Kalpana Thangavelu², Monika Sivaradhy¹, Kowsalya Veerappan¹, Anitha Gunalan¹

1. Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND

2. Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, IND

Corresponding author: Mugunthan M, dineshmugun@gmail.com

Abstract

Context: Acute undifferentiated febrile illness (AUFI) is characterized by a sudden onset of raised body temperature and is a common cause of hospital admission though not recognized as a disease state by the World Health Organization. Epstein-Barr virus (EBV) is reported to account for a significant occurrence of AUFI cases.

Aim: To know the role of EBV infection as a cause of acute undifferentiated febrile illness (AUFI).

Settings and design: We have used the combination of EBV serological assays to establish the role of the Epstein-Barr virus as the cause of acute undifferentiated febrile illness.

Methods and material: A total of 721 suspected cases of acute undifferentiated febrile illness which were tested negative for other common causes of acute febrile illness were selected for the study. Serum samples collected from these cases were tested for the presence of the EBV viral capsid antigen (VCA) IgM antibody. All positive serum samples were tested for the presence of EBV Epstein-Barr nuclear antigen (EBNA) IgG.

Statistical analysis used: Statistical analysis was performed with the help of Microsoft Excel software (Microsoft Corporation, Redmond, USA).

Results: Out of 721 suspected AUFI cases tested for EBV VCA IgM antibodies, 117 samples were positive and 604 were negative. All these 117 samples were tested for EBV EBNA IgG antibodies in which 88 were positive and 29 were negative. In our study, we found that around 4% (positive for VCA IgM and negative for EBNA IgG) of AUFI cases can be attributed to primary acute EBV infection.

Conclusions: EBV infection should be considered particularly in AUFI cases of less than five years of age even in those who do not meet the typical presentation of fever, lymphadenopathy and sore throat. Our study should help to raise awareness regarding the possibility of EBV infection particularly in AUFI cases. A high index of suspicion and timely diagnosis will definitely help clinicians to avoid a battery of investigations and misuse of antibiotics in cases of AUFI.

Categories: Allergy/Immunology, Infectious Disease, Other

Keywords: acute undifferentiated febrile illness, viral capsid antigen, epstein-barr nuclear antigen, ebv serology, epstein-barr virus

Introduction

Acute undifferentiated febrile illness (AUFI) is characterized by a sudden onset of raised body temperature without an apparent aetiology for two weeks duration and is a most frequent cause of hospital admission though not considered as a serious illness by the World Health Organization (WHO). Infectious aetiologies of AUFI lead to significant distress and mortality among children worldwide [1]. In countries like us where meagre resources impede diagnosis, clinical treatment is seldom reinforced by the knowledge of the cardinal regional pathogens [2-3]. The diagnostic approach in AUFI includes a thorough history taking and frequent physical examinations [4]. Predominant patients develop symptoms such as low-grade fever with rash, arthralgia, headache and myalgia with no apparent site of infection requiring laboratory confirmation for clinical management [5-7]. Malaria, typhoid, dengue, typhus and acute bacterial infections such as pneumonia are the major causes in resource-poor countries. In our own experience, we could make out that around 20%-30% of AUFI cases remain undiagnosed. Epstein-Barr virus (EBV) infection is a significant cause of AUFI cases though asymptomatic mostly [8-9]. Symptomatic EBV infection is difficult to be differentiated from those of other febrile illnesses [10-12]. Thus, the extent to which EBV causes AUFI remains unexplored. Using serological parameters like viral capsid antigen (VCA) IgM and Epstein-Barr nuclear antigen 1 (EBNA-1) IgG, acute and past EBV infections in immunocompetent individuals can be

How to cite this article

Dhodapkar R, M M, Thangavelu K, et al. (September 23, 2021) Epstein-Barr Virus: An Infrequent Pathogen of Acute Undifferentiated Febrile Illness From a Tertiary Care Hospital in Southern India. Cureus 13(9): e18207. DOI 10.7759/cureus.18207

differentiated [13-14]. The presence of VCA IgM in the absence of EBNA-1 IgG indicates acute infection. In our study, we have used the combination of these two serological assays to establish the role of the EBV as the cause of AUFI.

Materials And Methods

The aim of our study was to ascertain the role of EBV infection in AUFI patients who tested negative for all other typical microorganisms causing acute undifferentiated febrile illness. A total of 721 clinically suspected AUFI patients who were tested negative for malaria, arboviral (dengue, chikungunya), rickettsial (scrub typhus), leptospirosis and those with blood culture negative were included in the study (Figure 1). Serum samples collected from these suspected patients were tested for the appearance of EBV VCA IgM antibody by using Novalisa EBV VCA IgM enzyme-linked immunosorbent assay (ELISA) (NovaTec Immundiagnostica, Germany). Samples are considered positive if the absorbance value is higher than 11 Novalisa test units (NTU), and the absorbance value of less than 9 NTU is taken as negative. All positive serum samples were tested for the determination of EBV EBNA IgG by enzyme-linked fluorescence assay (ELFA) (Mini VIDAS, Biomerieux, France). Samples are considered positive if the test value is higher than 0.21 units, and the test value of less than 0.09 units is taken as negative. The Institutional Review Board approval was not obtained as the testing was performed with the archived samples preserved in our laboratory. Statistical analysis was performed with the help of Microsoft Excel 2007 (v12.0) (Microsoft Corporation Redmond, USA).

FIGURE 1: Flowchart of testing methodology followed for suspected AUFI cases
AUFI: acute undifferentiated febrile illness, EBV: Epstein-Barr virus, EBNA: Epstein-Barr nuclear antigen, VCA: viral capsid antigen.

Results

Seven hundred twenty-one suspected cases of AUFI were studied in which 415 (57%) were males, whereas 306 (43%) were females. The majority of cases were in the age group of 20-50 years (n=295), whereas children less than one year (n=87) and from one to five years (n=44) were the least (Figure 2). Out of 721 cases, 367 were outpatients, whereas 354 were admitted to the hospital for their management. EBV VCA IgM antibodies detection assay was done for these 721 cases, where 117 samples were positive and 604 were negative. Based on the result of EBV VCA IgM, around 16% of the suspected AUFI cases (117/721) could be attributed to EBV infection. All these 117 samples were tested for EBV EBNA IgG antibodies in which 88 were positive and 29 were negative. Twenty-nine out of 721 cases (4%) were positive for VCA IgM and negative for EBNA IgG which can be categorized as primary acute EBV infection. Both EBNA IgG and VCA IgM were positive in around 88 cases which can be regarded as either EBV recovery or reactivation. The

results are as tabulated in Table 1.

No of samples	Assay performed	Reactive (number and percentage)	Nonreactive (number and percentage)
721 (AUI cases)	EBV VCA IgM	117 & 16% (EBV infection)	604 & 84% (no EBV infection)
117 (EBV VCA IgM positive cases)	EBV EBNA IgG	88 & 96% (EBV recovery or reactivation)	29 & 4% (acute EBV infection)

TABLE 1: The results of the assays performed and their clinical interpretation

AUI: acute undifferentiated febrile illness, EBV: Epstein-Barr virus, VCA: viral capsid antigen, EBNA: Epstein-Barr nuclear antigen.

FIGURE 2: Age distribution of AUI cases (total 721)

AUI: acute undifferentiated febrile illness.

Discussion

EBV is a common viral disease especially in children and adolescents, and its symptoms resemble other febrile illnesses. Patients presenting with fever, sore throat, headache, rhinorrhea, chills and joint aches were tested for common causes of AUI. Our objective was to describe whether some of these AUI cases could be ascribed to EBV infection. Common modalities of EBV diagnosis include serological and molecular assays. The spectrum of serological assays for EBV includes nonspecific tests for the demonstration of heterophile antibodies (the monospot test), as well as EBV-specific assays that use different antigens with various interpretation criteria. With regards to the monospot test, there are multiple interfering factors which contribute to increased false negative results, decreasing the sensitivity and specificity as well. It has been described that in children less than four years, the sensitivity ranges between 27% and 76% [15-16]. Thus, EBV-specific antibody testing is recommended for the diagnosis of EBV [17]. We have used enzyme-linked immunosorbent assay for the detection of IgM antibodies against EBV VCA and enzyme-linked fluorescent assay for the detection of IgG antibodies against EBNA. According to Jensen, the detection of VCA IgM antibody is the most specific assay for the diagnosis of acute EBV infection [18]. The absence of EBNA-1 IgG indicates an acute infection, and their presence indicates past infection as per Sener et al. [19].

Most of our patients were adults of age group 20-50 years which is similar to a study by Grotto et al. in Israel [20], whereas Balasubramanian et al. [21] reported maximum incidence in the one to five years age group from Southern India. Other series from Turkey [22], Korea [23] and Taiwan [24] have shown similar trends in age wise incidence. The morbidity of primary EBV infection increases in patients more than 40 years of age. They may have protracted fever and serious hepatic involvement [25-26].

No gender preponderance was seen in our study as equivalent number of males and females were affected, but Son and Shin [23] from Korea noted an increasing male preponderance. No notable difference is seen in the number of patients from both outpatient and inpatient departments. The major concern in EBV disease is the detection of a primary/past or no infection [14]. Although the EBV genome codes for several nonstructural and structural genes, those encoding the EBNAs, the viral capsid antigens (VCAs) and the early antigens (EAs) are commonly detected. Therefore, the serological assays can distinguish the clinical forms of EBV [27]. Based on the outcome of our serological tests, we can categorize the AUFI cases into primary acute EBV infection and EBV recovery/reactivation.

Although the instinct is to utilise polymerase chain reaction (PCR) as a first-line test, it is documented that serology is more sensitive and specific than PCR to diagnose acute EBV infection. According to She et al., EBV DNA was demonstrated in only 70% of serology-proven acute EBV infection. Moreover, EBV reactivation cannot be detected even with highly sensitive PCR assay [28].

In our study, around 16% of the AUFI (117/721) cases could be attributed to EBV infection and around 4% (positive for VCA IgM and negative for EBNA IgG) of AUFI cases can be attributed to primary acute EBV infection. Masakhwe et al. reported that 29% of AUFI to be caused by EBV in Kenya [29].

Conclusions

The early primary EBV infection presents with mild, nonspecific illness or silent seroconversion. Classical infectious mononucleosis syndrome with typical clinical features is rare in India. Our study should help to raise awareness regarding the possibility of EBV infection particularly in AUFI cases who do not meet the typical presentation of fever, lymphadenopathy and sore throat. Appropriate awareness about EBV infection among clinicians can reduce diagnostic confusion with more ominous diseases like malignancy which it can closely mimic. A high index of suspicion and timely diagnosis will definitely help clinicians to avoid a battery of investigations and misuse of antibiotics in cases of AUFI.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. The informed consent was not obtained as the study was done on the stored serum samples. The Institutional Review Board approval was not obtained as the analysis was performed with the archived samples preserved in our laboratory. issued approval The informed consent was not obtained as the study was done on the stored serum samples. The Institutional Review Board approval was not obtained as the analysis was performed with the archived samples preserved in our laboratory. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Abhilash KP, Jeevan JA, Mitra S, et al.: Acute undifferentiated febrile illness in patients presenting to a tertiary care hospital in South India: clinical spectrum and outcome. *J Glob Infect Dis.* 2016, 8:147-54. [10.4103/0974-777X.192966](#)
2. Aregawi MW, Ali AS, Al-mafazy AW, et al.: Reductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008. *Malaria J.* 2011, 10:46. [10.1186/1475-2875-10-46](#)
3. Bouyou-Akotet MK, Mawili-Mboumba DP, Kendjo E, et al.: Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008. *Malaria J.* 2009, 8:300. [10.1186/1475-2875-8-300](#)
4. Tolan RW : Fever of unknown origin: a diagnostic approach to this vexing problem . *Clin Pediatr (Phila).* 2010, 49:207-13. [10.1177/0009922809347799](#)
5. Dhingra B, Mishra D: Early diagnosis of febrile illness: the need of the hour . *Indian Pediatr.* 2011, 48:845-9. [10.1007/s13312-011-0134-6](#)
6. Capeding MR, Chua MN, Hadinegoro SR, et al.: Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children. *PLoS Negl Trop Dis.* 2013, 7:e2331. [10.1371/journal.pntd.0002331](#)
7. Suttinont C, Losuwanaluk K, Niwatayakul K, et al.: Causes of acute, undifferentiated, febrile illness in rural Thailand: results of a prospective observational study. *Ann Trop Med Parasitol.* 2006, 100:363-70. [10.1179/136485906X112158](#)
8. Chow A, Robinson JL: Fever of unknown origin in children: a systematic review . *World J Pediatr.* 2011, 7:5-10. [10.1007/s12519-011-0240-5](#)
9. D'Acremont V, Kilowoko M, Kyungu E, et al.: Beyond malaria—causes of fever in outpatient Tanzanian children. *N Engl J Med.* 2014, 370:809-17. [10.1056/NEJMoa1214482](#)
10. Chan KH, Ng MH, Seto WH, Peiris JS: Epstein-Barr virus (EBV) DNA in sera of patients with primary EBV

- infection. *J Clin Microbiol*. 2001, 39:4152-4. [10.1128/JCM.39.11.4152-4154;2001](#)
11. Valachis A, Kofteridis D: Mononucleosis and Epstein-Barr virus infection: treatment and medication. *Virus Adapt Treat*. 2012, 4:23-8. [10.2147/VAAT.S17837](#)
12. Macsween KF, Higgins CD, McAulay KA, Williams H, Harrison N, Swerdlow AJ, Crawford DH: Infectious mononucleosis in university students in the United Kingdom: evaluation of the clinical features and consequences of the disease. *Clin Infect Dis*. 2010, 50:699-706. [10.1086/650456](#)
13. De Paschale M, Clerici P: Serological diagnosis of Epstein-Barr virus infection: problems and solutions. *World J Virol*. 2012, 1:31-43. [10.5501/wjv.v1.i1.31](#)
14. Gartner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, Mueller-Lantzsch N: Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. *Clin Diagn Lab Immunol*. 2005, 10:78-82. [10.1128/cdli.10.1.78-82.2003](#)
15. Marshall-Andon T, Heinz P: How to use ... the Monospot and other heterophile antibody tests. *Arch Dis Child Educ Pract Ed*. 2017, 102:188-93. [10.1136/archdischild-2016-311526](#)
16. Horwitz CA, Henle W, Henle G, et al.: Clinical and laboratory evaluation of infants and children with Epstein-Barr virus-induced infectious mononucleosis: report of 32 patients (aged 10-48 months). *Blood*. 1981, 57:933-8.
17. Ebell MH: Epstein-Barr virus infectious mononucleosis. *Am Fam Physician*. 2004, 70:1279-87.
18. Sener AG, Afsar I, Pinar E: Evaluation of Epstein-Barr virus antibodies, anti-VCA avidity by immunofluorescence and immunoblot assays for assessment of Epstein-Barr virus immunologic state. *J Virol Methods*. 2009, 159:300-2. [10.1016/j.jviromet.2009.04.009](#)
19. Grotto I, Mimouni D, Huerta M, et al.: Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults. *Epidemiol Infect*. 2003, 131:683-9. [10.1017/s0950268803008550](#)
20. Balasubramanian S, Ganesh R, Kumar JR: Profile of EBV associated infectious mononucleosis. *Indian Pediatr*. 2012, 49:837-8. [10.1007/s13312-012-0190-6](#)
21. Cengiz AB, Cultu-Kantaroglu O, Seçmeer G, Ceyhan M, Kara A, Gürgey K: Infectious mononucleosis in Turkish children. *Turk J Pediatr*. 2010, 52:245-54.
22. Son KH, Shin MY: Clinical features of Epstein-Barr virus-associated infectious mononucleosis in hospitalized Korean children. *Korean J Pediatr*. 2011, 54:409-13. [10.3345/kjp.2011.54.10.409](#)
23. Tsai MH, Hsu CY, Yen MH, et al.: Epstein-Barr virus-associated infectious mononucleosis and risk factor analysis for complications in hospitalized children. *J Microbiol Immunol Infect*. 2005, 38:255-61.
24. Auwaerter PG: Infectious mononucleosis in middle age. *JAMA*. 1999, 281:454-9. [10.1001/jama.281.5.454](#)
25. Horwitz CA, Henle W, Henle G, Schapiro R, Borken S, Bundtzen R: Infectious mononucleosis in patients aged 40 to 72 years: report of 27 cases, including 3 without heterophil-antibody responses. *Medicine*. 1983, 62:256-62. [10.1097/00005792-198307000-00005](#)
26. Macsween KF, Crawford DH: Epstein-Barr virus—recent advances. *Lancet Infect Dis*. 2003, 3:131-40. [10.1016/s1473-3099\(03\)00543-7](#)
27. Jenson HB: Epstein-Barr virus. *Nelson Textbook of Pediatrics: First South East Asia Edition*. Kliegman RM, Stanton BF, St. Geme JW 3rd, Schor NF, Behrman RE (ed): Elsevier, Amsterdam, Netherlands; 2016. 1586-90.
28. She RC, Stevenson J, Phansalkar AR, Hillyard DR, Litwin CM, Petti CA: Limitations of polymerase chain reaction testing for diagnosing acute Epstein-Barr virus infections. *Diagn Microbiol Infect Dis*. 2007, 58:333-5. [10.1016/j.diagmicrobio.2007.01.014](#)
29. Masakhwe C, Ochanda H, Nyakoe N, Ochiel D, Waitumbi J: Frequency of Epstein-Barr virus in patients presenting with acute febrile illness in Kenya. *PLoS One*. 2016, 11:e0155308. [10.1371/journal.pone.0155308](#)